NASDAQ · WVE

Wave Life Sciences Ltd.

$5.81 +$0.03 (+0.52%) 1D After hours

Key Metrics

$1.12B
Market cap
53.77×
P/E · TTM
$29.07M
Revenue · TTM
$20.79M
Net income
EPS · TTM $0.13
Dividend yield
Free cash flow
Beta · 1Y 1.05
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 10
    From its Feb 26 high, the share price fell 63%.

    Peak close $15.36 on Feb 26; trough close $5.66 on Jun 10. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -63%
  • Mar 31
    The stock moved +9.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 31
  • Mar 26
    The stock moved -49.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.12B
Enterprise value
Shares outstanding192.4M
52-wk range$5.02 – $21.73
Avg volume · 20D1.3M
Net cash
Book value / share$3.15
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Wave Life Sciences Ltd.
IPO dateNov 11, 2015
Employees317

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E53.77
P/S38.45
P/FCF
EV/EBITDA
EV/Sales
Graham №$3.01

Profitability

Gross
Operating 71.5%
Net 71.5%
FCF
ROE / ROIC 4.1% · —

Financial Health

Current ratio11.26
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$511.44M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

7.3
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$3.01 vs $5.81
Trades 1.9× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings